Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amivantamab versus cetuximab with mFOLFOX6 or FOLFIRI as first-line treatment for left-sided RAS/BRAF wild-type metastatic colorectal cancer
CTR20244582Phase 3Active
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of amivantamab and cetuximab in colorectal cancer (CRC) (4 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Progression-free survival by blinded independent central review. Started Jan 2026; status: active.
02
Drugs
amivantamabcetuximab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on CTR20244582.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244582.